Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Nuformix Plc ( (GB:NFX) ).
Nuformix has secured U.S. Food and Drug Administration Orphan Drug Designation for tranilast lystate, the inhaled active substance in its NXP002 programme targeting idiopathic pulmonary fibrosis, a rare and high-mortality lung disease. The designation, which follows a similar status already granted in Europe, provides development incentives such as tax credits, fee waivers and potential market exclusivity, strengthening Nuformix’s hand in ongoing licensing discussions and enhancing the programme’s strategic value for future partners.
The dual U.S. and European orphan status reinforces Nuformix’s positioning in the niche fibrosis space and could accelerate the progression of NXP002 toward clinical and commercial milestones. For stakeholders, the move underlines the company’s ability to convert its drug repurposing model into tangible regulatory assets that may improve partnering prospects and support long-term value creation, despite the programme still being at a preclinical stage.
The most recent analyst rating on (GB:NFX) stock is a Hold with a £0.25 price target. To see the full list of analyst forecasts on Nuformix Plc stock, see the GB:NFX Stock Forecast page.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Neutral.
The score is held down primarily by weak financial performance—zero recent revenue, ongoing losses, and persistent negative free cash flow—despite the benefit of no debt. Technicals add downside risk with price below key short/medium-term averages and negative MACD, while valuation is also constrained by a negative P/E and no dividend support.
To see Spark’s full report on GB:NFX stock, click here.
More about Nuformix Plc
Nuformix plc is a UK-listed pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. It applies its expertise in discovering, developing and patenting novel drug forms with improved physical properties to create differentiated products, opening new commercial opportunities and early-stage licensing potential from a pipeline of preclinical assets.
Average Trading Volume: 29,605,576
Technical Sentiment Signal: Buy
Current Market Cap: £5.49M
Find detailed analytics on NFX stock on TipRanks’ Stock Analysis page.